Follow

Bondholders approve amendment to bond terms and conditions

14 January 2022 - 17:23

ADDvise Group AB (publ) (the "Company") today announces the successful completion of the written procedure that was initiated on 16 December 2021 (the "Written Procedure") in relation to the Company's outstanding up to SEK 500,000,000 senior secured bonds with ISIN SE0015222088 (the "Bonds"), that sought approval from bondholders ("Bondholders") for certain amendments to the terms and conditions of the Bonds (the "Proposal").

A sufficient number of bondholders participated in the written procedure in order to form a quorum, and a requisite majority of the bondholders voted in favour to approve the Proposal.

Each Bondholder is eligible to receive a consent fee in an amount equal to 0.75 per cent of the nominal amount of each Bond held by the relevant Bondholder on the Consent Fee Record Date (as defined in the Written Procedure) which will be 21 January 2022. Settlement of the consent fee is expected to occur on 28 January 2022.

The conditions for payment of the consent fee are specified in detail in the formal and detailed notice of the Written Procedure and are available on the Company's website, www.addvisegroup.com.
 

For further information, please contact:

Hanna Myhrman, General Counsel
+46 709 82 92 23
[email protected]


About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, [email protected], is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Provided by: Cision
Nasdaq First North GM (Sweden)
ADDvise Group AB
ADDvise Group develops and markets equipment and services to healthcare and research facilities....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More